drugset / Trial / NCT07825753
Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the clinical efficacy (objective response rate, ORR) of mass spectrometry-based absolute quantification-guided selection and matching of ADC/PDC therapy in patients with locally advanced or metastatic pancreatic cancer/breast cancer, and to explore a quantitative threshold-based stratification strategy for identifying a "hidden benefit population
Timeline
- Start
- 2026-09-10
- Primary completion
- 2027-09-01
- Completion
- 2030-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BL-B01D1 | Unknown | — | Intravenous |
| Subject | Becotatug Vedotin | Other / unclassified | — | Intravenous |
| Subject | Datopotamab deruxtecan | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | Enfortumab Vedotin | Other / unclassified | 1.25 mg/kg | Intravenous |
| Subject | Mirvetuximab Soravtansine | Other / unclassified | 6 mg/kg | Intravenous |
| Subject | Sacituzumab Govitecan | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Trastuzumab deruxtecan | Monoclonal antibody | 5.4 mg/kg | Intravenous |
| Subject | Trastuzumab emtansine | Other / unclassified | 3.6 mg/kg | Intravenous |